Oncology Group [ECOG] scoring system). Epidermal growth growth factor receptor (EGFR) expression was estimated in serum using reverse transcriptase polymerase chain reaction (RT-PCR) at baseline and following four cycles of Carboplatin -Paclitaxel chemotherapy. Response was assessed using the RECIST 1.1 criteria. Objective response rate (ORR) was defined as Complete remission (CR) or partial response (PR) and Disease control rate (DCR) was defined as CR/PR/Stable disease (SD). Kaplan meier curve was used to compare the overall survival (OS) between subjects based on median EGFR expression level as the cut-off. Results: A total of 82 subjects were enrolled. These included 79 (96.3%) males with mean (SD) age of 61.9 (9.8) years and 48.8% having metastatic disease. Majority were current / former smokers (97.6%); 59.7% had KPS ranging between 40 -70 and 48.1% had ECOG of 0/II. The baseline mean (± SD) serum EGFR expression was 17.8 ± 9.3 fold increase over control values, with median (min., max.) of 18.2 (4.4, 42.8). Following chemotherapy, ORR and DCR were 59.7% and 77.3% respectively. Significant reduction in EGFR expression was observed with median (min, max.) absolute and percentage reduction of 6.2 fold (−3.1, 33.6), and 54.2 % (−55.6, 78.4) respectively; p < 0.001. No significant association was observed between change in EGFR expression and age, gender, disease stage, performance status, ORR or DCR. Subjects with baseline EGFR expression of greater than 16.0 fold had significantly worse OS than those with <16.0 fold increase. Conclusions: EGFR is over-expressed in advanced squamous cell lung cancer and is significantly downregulated following chemotherapy; additionally, baseline expression is a useful marker of overall survival following chemotherapy.
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Plasma circulating ctDNA: Potential biomarker in non-small cell lung carcinoma and clinical significance Background: Circulating cell free tumour DNA (ctDNA) from liquid biopsy is a potential source of tumour genetic material especially in case of non-availability of tissue biopsy for EGFR testing. Detectable levels of oncogenic driver mutations in peripheral blood have been shown to be associated with poorer prognosis and good predictor of EGFR TKI efficacy. Methods: Liquid biopsy was performed on 95 NSCLC patients with matched tumour tissue for genomic analysis. An EGFR mutation of one major molecular subtype in NSCLC was performed on massive parallel sequencing. Single gene EGFR mutation analysis was performed on the ctDNA by using ultra deep sequencing on the HiSeq platform. Then custom designed bioinformatics algorithms were used to detect somatic mutations at allele frequencies as low as 0.01%. Results: Overall concordance of mutation status between 95 pairs of tissue and plasma ctDNA samples for EGFR mutation status was about 93%. 30.5% (29/95) of the study subset was EGFR mutated on tissue typing and 27.36% (26/95) in ctDNA. Positive predictive value was 100% and negative predictive value was 95.6% -with diagnostic accuracy of 97%. A false negative rate of 4% was observed in this study. 12 out of 95 (12.63%) samples which had rare Exon19 deletions and complex indels could be confidently detected by NGS methods only. An objective efficacy response rate for Gefitinib was estimated at 70%, with a disease control rate of 94%. Median period of follow-up was 13.9 months. Median PFS was 16.8 months (95% CI 11. 168-26.198) . Conclusions: 12% of newly diagnosed NSCLC patients could get the additional benefit of targeted therapy, by using the NGS which detected oncogenic driver mutations. Liquid Biopsy offer significant diagnostic, prognostic, and predictive information. 
